Patent · US Active

Macrocyclic inhibitors of hepatitis C virus

US8012939B2 · kind B2 · utility

7Cited by

7References

11Claims

0Family size

Assignees

Tibotec Pharmaceuticals Ltd. · IE
MEDIVIR AB · SE

Inventors

Kenneth Alan Simmen · Tervuren, BE
Herman Augustinus De Kock · Arendonk, BE
Pierre Jean-Marie Bernard Raboisson · Sligo, IE
Sandrine Marie Helene Vendeville · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE
Lili Hu · Mechelen, BE
Abdellah Tahri · Anderlecht, BE
Dominique Louis Nestor Ghislain Surleraux · Braine-le-Comte, BE
Wim Van De Vreken · Haasdonk, BE
Ismet Dorange · Nacka, SE
Yvan Rene Ferdinand Simonnet · Rouen, FR
Karl Magnus Nilsson · Vimmerby, SE
Bengt Bertil Samuelsson · Skärholmen, SE
Asa Annica Kristina Rosenquist · Huddinge, SE
Hans Wallberg · Stuvsta-Snättringe, SE

Key dates

Filing date	Jul 28, 2006
Grant date	Sep 6, 2011
Priority date	—
Expiry date	Mar 3, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K5/06191
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Inhibitors of HCV replication of formula (I)and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.